London – Positive results from the T2NOW Phase III trial demonstrated significant reduction in A1C, a marker of average blood sugar, for patients treated with Forxiga (dapagliflozin) compared with patients receiving placebo.1,2 Adjusted mean change in A1C was −0.62% for Forxiga versus +0.41% for placebo, a difference of −1.03% (95% CI: -1.57-0.49; p<0.001). Statistical significance was achieved in the primary endpoint and in all …
Ottawa – October is Autism Awareness Month, where we come together to increase understanding and awareness of autism and to help end the stigma and discrimination that some Autistic people experience. It is estimated that 1 in 50 children and youth aged 1 to 17 have been diagnosed with autism spectrum disorder in Canada. Autism is often referred to as a spectrum …
MacTier – Robert Oliphant, Parliamentary Secretary to the Minister of Foreign Affairs and Member of Parliament for Don Valley West and John M. Rafferty, President and CEO, Canadian National Institute for the Blind (CNIB), announced a federal investment of more than $2.3 million to support retrofits to a number of buildings at the CNIB’s Lake Joe camp in MacTier, Ontario. This investment will enable CNIB to …
NEW YORK – The US health officials can endorse a common antibiotic as a morning-after pill that gay and bisexual men can use to try to avoid some increasingly common sexually transmitted diseases. The guideline is specific to the group that has been most studied – gay and bisexual men and transgender women who had an STD in the previous …
Local pharmacies now a one-stop-shop for 19 common ailments as Ontario expands list of medications pharmacists can prescribe TORONTO — The Ontario government is making it more convenient for people to connect to care closer to home by allowing pharmacists to treat and prescribe medications for an additional six common medical ailments. This is in addition to the 13 common ailments that …
Ottawa – Health Canada has authorized the use of the Pfizer-BioNTech Comirnaty COVID-19 vaccine targeting the Omicron XBB.1.5 subvariant for individuals six months of age and older. Health Canada received Pfizer-BioNTech’s submission on June 29, 2023. After a thorough and independent review of the evidence, Health Canada has determined that the vaccine meets the Department’s stringent safety, efficacy and quality requirements. …
Ottawa – Canada is facing an unrelenting and tragic toxic drug and overdose crisis that has left no community untouched. Family members, friends, and neighbours are losing their lives to one of the most serious public health crises in our country’s history. The national data release on opioid and stimulant-related harms tells us that this crisis continues. According to the latest …
Ottawa – Palliative care is a critical part of Canada’s health care system as it helps improve the quality of life for as long as possible. For many that means care at home or in the communities where they live. In 2022, more than half of Canadians received palliative care before the end of their lives. The Government of Canada …
KIRKLAND – The National Advisory Committee on Immunization (NACI) recently provided a strong recommendation for PREVNAR 20 for the following adult populations who have not been previously immunized with a pneumococcal vaccine or whose vaccination status is unknown: Adults ≥65 years of age Adults 50-64 years of age living with risk factors placing them at higher risk of pneumococcal disease. …
Boston – Alexion, AstraZeneca Rare Disease, has completed a definitive purchase and licence agreement for a portfolio of preclinical rare disease gene therapy programmes and enabling technologies from Pfizer Inc. (Pfizer). These new resources build on the combined capabilities of Alexion and AstraZeneca in genomic medicine, with the objective to develop new genetic therapies with improved safety and efficacy profiles. …
